EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Sandra Torres iD, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc iD, Maximilian Joseph Brol, Frank Erhard Uschner und 10 weitere

Hepatology · 2023-04 · 77 (4) · 1228-1240

DOI: 10.1002/hep.32746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology, online erschienen am 13.10.2022. Verfasst von Sandra Torres und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I , Goethe University Clinic Frankfurt , Frankfurt , Germany. Hauptthemen laut MEDLINE: Janus Kinase 2, Liver Cirrhosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibrotic role of the JAK2 inhibitor pacritinib on activated hepatic stellate cells (HSCs) in vitro and in two animal models of liver fibrosis in vivo . Approach and Results: Transcriptome analyses of JAK2 in human livers and other targets of pacritinib have been shown to correlate with profibrotic factors. Although transcription of JAK2 correlated significantly with type I collagen expression and other profibrotic genes, no correlation was observed for interleukin‐1 receptor‐associated kinase and colony‐stimulating factor 1 receptor. Pacritinib decreased gene expression of fibrosis markers in mouse primary and human‐derived HSCs in vitro . Moreover, pacritinib decreased the proliferation, contraction, and migration of HSCs. C 57 BL/6J mice received ethanol in drinking water (16%) or Western diet in combination with carbon tetrachloride intoxication for 7 weeks to induce alcoholic or nonalcoholic fatty liver disease. Pacritinib significantly reduced liver fibrosis assessed by gene expression and Sirius red staining, as well as HSC activation assessed by alpha‐smooth muscle actin immunostaining in fibrotic mice. Furthermore, pacritinib decreased the gene expression of hepatic steatosis markers in experimental alcoholic liver disease. Additionally, pacritinib protected against liver injury as assessed by aminotransferase levels. Conclusions: This study demonstrates that the JAK2 inhibitor pacritinib may be promising for the treatment of alcoholic and nonalcoholic liver fibrosis and may be therefore relevant for human pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Liver CirrhosisHumansMiceAnimalsLiverBridged-Ring CompoundsFibrosisHepatic Stellate CellsPyrimidines

Substanzen

Janus Kinase 2Bridged-Ring Compounds11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,1…Pyrimidines

Autor:innen und Institutionen

  • Department of Internal Medicine I , Goethe University Clinic Frankfurt , Frankfurt , Germany.
  • Department of Cell Death and Proliferation , Instituto Investigaciones Biomédicas de Barcelona (IIBB), Spanish National Research Council (CSIC) , Barcelona , Spain.
  • Liver Unit-IDIBAPS and Centro de Investigación Biomédica en Red (CIBERehd) , Barcelona , Spain.
  • Department of Internal Medicine B , University of Münster , Münster , Germany.
  • Department of Diagnostic and Interventional Radiology , Universit+y Hospital Frankfurt , Frankfurt am Main , Germany.
  • Research and Development Department , Linxis BV , Amsterdam , The Netherlands.

ORCID-Profile: Sandra Torres, Olaf Tyc, Jonel Trebicka

Zitieren

APA

Torres, S., Ortiz, C., Bachtler, N., Gu, W., Grünewald, L. D., Kraus, N., Schierwagen, R., Hieber, C., Meier, C., Tyc, O., Joseph Brol, M., Uschner, F. E., Nijmeijer, B., Welsch, C., Berres, M. L., Garcia-Ruiz, C., Fernandez-Checa, J. C., Trautwein, C., Vogl, T. J., …, & Klein, S. (2023). Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis. Hepatology, 77(4), 1228-1240. https://doi.org/10.1002/hep.32746

Vancouver

Torres S, Ortiz C, Bachtler N, Gu W, Grünewald LD, Kraus N, et al. Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis. Hepatology. 2023;77(4):1228-1240. doi:10.1002/hep.32746

BibTeX
@article{Torres2023,
  author = {Torres, Sandra and Ortiz, Cristina and Bachtler, Nadine and Gu, Wenyi and Grünewald, Leon D and Kraus, Nico and Schierwagen, Robert and Hieber, Christoph and Meier, Caroline and Tyc, Olaf and Joseph Brol, Maximilian and Uschner, Frank Erhard and Nijmeijer, Bart and Welsch, Christoph and Berres, Marie-Luise and Garcia-Ruiz, Carmen and Fernandez-Checa, Jose Carlos and Trautwein, Christian and Vogl, Thomas J and Zeuzem, Stefan and Trebicka, Jonel and Klein, Sabine},
  title = {Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis},
  journal = {Hepatology},
  year = {2023},
  volume = {77},
  number = {4},
  pages = {1228--1240},
  doi = {10.1002/hep.32746}
}
Kostenlos starten →